IMPEDIMED LIMITED — Board/Management Information 2017

Apr 9, 2017

==> picture [226 x 43] intentionally omitted <==

10[th] April 2017

ASX ANNOUNCEMENT

BOARD OF DIRECTORS APPOINTMENT

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced it has appointed Ms Judith Downes as a non-Executive Director.

Ms Downes brings over 20 years of accounting and senior management expertise to the Board with a strong focus on financial management and audit and risk management, with large ASX listed companies, as an executive and Director. During her executive career she held the roles of Chief Financial Officer (CFO) at Alumina Limited (ASX: AWC) and as CFO / COO of Institutional Division, ANZ Banking Group Limited (ASX: ANZ).

Ms Downes currently serves as Board Chairman of Bank Australia Limited, and as a member of The Financial Reporting Council of Australia. She has also previously served as a Director of Devine Limited (ASX: DVN), Alcoa of Australia, ING Australia and the ANZ Staff Superannuation Fund. She is a Fellow of the CPA, Chartered Accountants Australia and New Zealand, and Australian Institute of Company Directors. Ms Downes is an Honorary Fellow of the University of Melbourne’s Faculty of Business and Economics and is also a member of the University of Melbourne’s finance committee.

Ms Downes will serve as one of the company’s Australian-based directors, replacing Elizabeth Gaines, who stood down in February 2017 to take on a full time executive position.

Chair of ImpediMed, Dr Cherrell Hirst said: “We are very excited to welcome a Director of the calibre and experience of Judith, enhancing the financial expertise on the Board. This appointment is part of our ongoing process to build an exceptional and capable Board with the relevant skills to guide the company through its next growth phase, as it expands its commercial presence globally and forges its position as a leader in digital health for the management of lymphoedema and chronic heart failure.”

Cherrell Hirst, AO Chairman

For further information, contact: Richard Carreon, ImpediMed Managing Director & CEO T: +1 (760) 585-2100

Investor and media contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.